本文選題：毛囊間充質(zhì)干細(xì)胞 + 誘導(dǎo)分化��； 參考：《吉林大學(xué)》2012年碩士論文

【摘要】：缺血性心肌病是全球發(fā)病率和死亡率最高的疾病之一，由于心肌再生能力有限，幾乎不能通過(guò)自身增殖來(lái)修復(fù)損傷，只能靠瘢痕組織進(jìn)行修復(fù)；而通過(guò)瘢痕組織修復(fù)的心肌，，一方面由于收縮力差導(dǎo)致血液的輸出量不足，影響到心肌病患者的日常生活；另一方面由于其生物力學(xué)強(qiáng)度弱，可能會(huì)導(dǎo)致心臟突然破裂而猝死。傳統(tǒng)的藥物、介入治療和外科手術(shù)治療雖可部分恢復(fù)心肌梗死區(qū)的血供，但只能從一定程度上緩解癥狀，不能從根本上改善患者的生活質(zhì)量，提高生存率。而對(duì)心力衰竭患者而言，異體心臟移植是唯一有效的手段。但因供體心臟的來(lái)源有限，又阻礙了患者的治療。為解決供體心臟來(lái)源不足的問題，曾嘗試用與人類心臟類似的動(dòng)物心臟（比如豬的心臟）來(lái)進(jìn)行心臟移植，但由于存在嚴(yán)重的免疫排斥反應(yīng)、動(dòng)物源性疾病傳播和倫理問題，使其無(wú)法得以應(yīng)用。 基于以上原因，人們把目光轉(zhuǎn)向細(xì)胞療法修復(fù)損傷的心肌。倍受關(guān)注的就是干細(xì)胞，干細(xì)胞具有強(qiáng)大的自我更新和分化潛能，其為心肌損傷的治療提供了新的希望。研究表明，將干細(xì)胞移植入損傷的心肌后，可修復(fù)損傷的心肌，改善心臟功能。因此，干細(xì)胞療法越來(lái)越成為人們關(guān)注的焦點(diǎn)。根據(jù)干細(xì)胞分化潛能，可分為全能干細(xì)胞（即胚胎干細(xì)胞），多潛能干細(xì)胞（如間充質(zhì)干細(xì)胞）和單能干細(xì)胞（如角朊干細(xì)胞）。由于胚胎干細(xì)胞存在倫理和安全性問題，臍帶血干細(xì)胞具有疾病傳播的危險(xiǎn)，骨髓間充質(zhì)干細(xì)胞受取材不便和年齡限制，而人毛囊間充質(zhì)干細(xì)胞可克服以上述弊端，其具有來(lái)源豐富、取材方便、獲取不受年齡限制且增殖能力強(qiáng)的優(yōu)勢(shì)，所以有望成為細(xì)胞療法或構(gòu)建組織工程器官的首選種子源。 本實(shí)驗(yàn)首先分離、培養(yǎng)并鑒定了人毛囊間充質(zhì)干細(xì)胞，然后進(jìn)行新生大鼠心肌原代細(xì)胞分離、培養(yǎng)和純化，最后利用新生大鼠心肌細(xì)胞的條件培養(yǎng)基誘導(dǎo)人毛囊間充質(zhì)干細(xì)胞，探討人毛囊間充質(zhì)干細(xì)胞向心肌樣細(xì)胞分化的潛能。
[Abstract]:Ischemic cardiomyopathy is one of the diseases with the highest morbidity and mortality in the world. Because of the limited ability of myocardial regeneration, the damage can hardly be repaired by self-proliferation, but can only be repaired by scar tissue. On the one hand, poor contractility leads to insufficient blood output, which affects the daily life of patients with cardiomyopathy; on the other hand, it may lead to sudden cardiac rupture and sudden death because of its weak biomechanical strength. Although the traditional drugs, interventional therapy and surgical treatment can partially restore the blood supply in myocardial infarction area, they can only alleviate the symptoms to a certain extent, and cannot fundamentally improve the quality of life and the survival rate of the patients. For patients with heart failure, allograft heart transplantation is the only effective means. However, the limited source of donor heart hinders the treatment of patients. To solve the problem of insufficient donor heart sources, an attempt was made to use animal hearts similar to human hearts (such as pig hearts) for heart transplants, but due to severe immune rejection, the spread of animal-derived diseases and ethical problems. Make it impossible to use. For these reasons, people turn to cell therapy to repair damaged myocardium. Stem cells, which have strong self-renewal and differentiation potential, provide new hope for the treatment of myocardial injury. Studies have shown that transplantation of stem cells into the injured myocardium can repair the damaged myocardium and improve cardiac function. Therefore, stem cell therapy has increasingly become the focus of attention. According to the differentiation potential of stem cells, they can be divided into totipotent stem cells (i.e. embryonic stem cells), multipotent stem cells (such as mesenchymal stem cells) and monopotent stem cells (such as keratinocytes stem cells). Due to ethical and safety problems of embryonic stem cells, umbilical cord blood stem cells are at risk of disease transmission, bone marrow mesenchymal stem cells are inconvenient and age limited, and human hair follicle mesenchymal stem cells can overcome these disadvantages. It has the advantages of abundant sources, convenient material collection, no age restriction and strong proliferative ability, so it is expected to be the preferred seed source for cell therapy or for the construction of tissue engineering organs. Human hair follicle mesenchymal stem cells (HMSCs) were isolated, cultured and identified firstly, then isolated, cultured and purified from neonatal rat cardiac myocytes. Finally, human hair follicle mesenchymal stem cells were induced by conditioned medium of neonatal rat cardiomyocytes. To investigate the potential of human hair follicle mesenchymal stem cells to differentiate into cardiomyocyte-like cells.
【學(xué)位授予單位】：吉林大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2012
【分類號(hào)】：R329

【參考文獻(xiàn)】

相關(guān)期刊論文 前2條

1 楊珂;余瑾;楊恬;;表皮干細(xì)胞體外誘導(dǎo)轉(zhuǎn)分化為角膜上皮細(xì)胞的實(shí)驗(yàn)研究[J];第三軍醫(yī)大學(xué)學(xué)報(bào);2006年07期

2 李睿書;王石泉;;毛囊干細(xì)胞[J];細(xì)胞生物學(xué)雜志;2007年04期

本文編號(hào)：2109980